MYLAN-TERAZOSIN TABLET

Quốc gia: Canada

Ngôn ngữ: Tiếng Anh

Nguồn: Health Canada

Thành phần hoạt chất:

TERAZOSIN HYDROCHLORIDE

Sẵn có từ:

MYLAN PHARMACEUTICALS ULC

Mã ATC:

G04CA03

INN (Tên quốc tế):

TERAZOSIN

Liều dùng:

5MG

Dạng dược phẩm:

TABLET

Thành phần:

TERAZOSIN HYDROCHLORIDE 5MG

Tuyến hành chính:

ORAL

Các đơn vị trong gói:

100

Loại thuốc theo toa:

Prescription

Khu trị liệu:

ALPHA-ADRENERGIC BLOCKING AGENTS

Tóm tắt sản phẩm:

Active ingredient group (AIG) number: 0121210001; AHFS:

Tình trạng ủy quyền:

CANCELLED POST MARKET

Ngày ủy quyền:

2016-06-28

Đặc tính sản phẩm

_ _
_ _
_Page 1 of 39_
PRODUCT MONOGRAPH
PR
MYLAN-TERAZOSIN
Terazosin Hydrochloride Tablets
1 mg, 2 mg 5 mg and 10 mg
Antihypertensive Agent
Symptomatic Treatment of Benign Prostatic Hyperplasia (BPH)
Mylan Pharmaceuticals ULC
85 Advance Road
Etobicoke, ON
M8Z 2S6
Date of Revision:
November 17, 2014
Submission Control No: 179465
_ _
_ _
_Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
.................................................................................................
10
DRUG INTERACTIONS
.................................................................................................
13
DOSAGE AND ADMINISTRATION
.............................................................................
14
OVERDOSAGE
...............................................................................................................
16
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 16
STORAGE AND STABILITY
.........................................................................................
19
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 19
PART II: SCIENTIFIC INFORMATION
...............................................................................
20
PHARMACEUTICAL INFORMATION
.........................................................................
20
CLINICAL TRIALS
.........................................................................................................
21
DETAILED PHARMACOLOGY
.